ROSWELL PARK CANCER INSTITUTE CORP
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer is a funding opportunity from ROSWELL PARK CANCER INSTITUTE CORP, up to 468436, closing March 31, 2028.
Mar 31, 2028
(609d left)Overview
PROJECT SUMMARY/ABSTRACT Overexpression of Cyclin D1 (CCND1) is recognized as a major resistance mechanism to HER2 targeting agents. Patients with CCND1 amplification have the worst response to trastuzumab-containing therapy, and CCND1 overexpression is enough to render cancer cells insensitive to HER2 inactivation.…